Aethylaethyl(methoxymethyl)phosphinat | 27286-35-7

• 分子结构分类: 有机化合物 - 有机磷化合物
• 英文名称: Aethylaethyl(methoxymethyl)phosphinat
• 英文别名: 1-[Ethyl(methoxymethyl)phosphoryl]oxyethane
• CAS: 27286-35-7
• 化学式: C₆H₁₅O₃P
• 分子量: 166.157
• InChiKey: ZLOKADVNDKNJRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  乙醇 、 Aethyl(methoxymethyl)phosphinicchlorid 以 乙醚 为溶剂， 生成 Aethylaethyl(methoxymethyl)phosphinat
  参考文献：
  名称：

  Tsivunin,V.S. et al., Journal of general chemistry of the USSR, 1970, vol. 40, p. 568 - 573

  摘要：

  DOI：

文献信息

• Ether Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239920A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an ether (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  提供了有关制备抑制补体因子D的化合物、使用方法和制备过程，所述化合物包括具有式I的化合物，或其药用可接受的盐或组合物，其中A组上的R12或R13是醚（R32）。本文描述的抑制剂靶向因子D并在替代性补体途径的早期和关键点上抑制或调节补体级联，并减少因子D调节经典和凝集素补体途径的能力。本文描述的因子D抑制剂能够减少过度激活的补体，这与某些自身免疫、炎症和神经退行性疾病、缺血再灌注损伤和癌症有关。
• ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20160362433A1

  公开（公告）日：2016-12-15

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an ether (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement.
• US9732104B2
  申请人：——

  公开号：US9732104B2

  公开（公告）日：2017-08-15